Purpose of review This review will report on the new aspects of management of 'malignant' middle cerebral artery (MCA) infarctions.
INTRODUCTION
Large hemispheric infarctions because of middle cerebral artery (MCA) or internal carotid artery (ICA) occlusion constitute a major cause of severe morbidity and mortality. Neurological deterioration occurs as a consequence of space-occupying cerebral edema in approximately 10% of all hemispheric strokes and 5% of all ischemic strokes which led to the term 'malignant MCA infarction' [1] [2] [3] . Mortality ranges between 41 and 79% with conservative treatment in the intensive care unit [1] [2] [3] [4] [5] . However, the new era of decompressive craniectomy resulted in a dramatic decrease of mortality and severe disability [6] [7] [8] [9] .
The patients affected are generally 10 years younger (56 AE 9.4 years) than the average stroke patient [1] . The incidence ranges between 10 and 20 per 100 000 per year [1] .
Large hemispheric infarctions occur as a consequence of a thrombotic or embolic occlusion of the distal ICA or the proximal MCA trunk without sufficient collateral flow (Figs 1 and 2) . Depending on the presence of sufficient collaterals, mainly leptomeningeal arteries, or anatomic variants, the infarction may include the anterior and/or posterior territory as well [10, 11] .
Most patients have risk factors for vascular disease such as hypertension, diabetes, hypercholesteremia, tobacco abuse, history of transient ischemic attacks or ischemic strokes, congestive heart failure, and coronary artery disease. Atrial fibrillation is more frequent in patients with MCA and ICA territory strokes compared to the remaining stroke population [1] [2] [3] 12] . ICA dissection is a significant cause of large territory infarctions in younger patients (12%) [12] .
The patients present with hemiparesis, hemiplegia, hemisensory loss, homonymous hemianopia contralateral to the site of infarction, partial and
The most reliable predictors of a 'malignant' course of large hemispheric strokes are infarction of more than 50% of the MCA territory and a perfusion deficit of more than 66% on CT as well as stroke volume in diffusion-weighted imaging of greater than 145 ml within 14 h and greater than 82 ml within 6 h of symptom onset.
Close neuromonitoring with continuous EEG, intracortical electrodes, microdialysis, and brain tissue oxygenation may be helpful in early detection of development of cerebral edema.
Recanalization of the affected artery utilizing a combination of intravenous and intra-arterial thrombolysis and/or mechanical thrombectomy within 3-6 h, as early as possible, should be attempted.
Monitoring of intracranial pressure has not been proven helpful. ICP can be normal in the setting of herniation.
Decompressive surgery within 48 h after symptom onset in patients less than 60 years old reduces mortality, moderate (mRS 3) and severe disability (mRS 4). The number needed to treat (NNT) for survival and severe disability is 2, the NNT for moderate disability equals 6. hemispheric infarctions; cerebral hypoperfusion is not the cause for early neurological deterioration brain death [1, 14, 15 & ].
PREDICTORS OF MALIGNANT MIDDLE CEREBRAL ARTERY INFARCTION
With increasing availability of decompressive craniectomy as an aggressive treatment option, identification of predictors of a malignant course of the MCA or ICA infarction is exceedingly important. Several clinical and radiological predictors of development of brain swelling and poor outcome are summarized in Table 1 [2, 11, . The metaanalysis by Hofmeijer et al. [41] included 23 studies and found involvement of more than 50% of the MCA territory (Fig. 3 ) and a perfusion deficit of more than 66% on computed tomography (CT) to be the most reliable predictors of edema formation. Other associated predictors with moderate effect size were early mass effect, involvement of other vascular territories, higher body temperature, ICA occlusion, and mechanical ventilation. A head CT showing ischemic infarction of more than twothirds of the MCA territory with either involvement of the basal ganglia or evidence of developing cerebral edema was also chosen as inclusion criterion in two randomized hemicraniectomy trials [6, 7] . Utilizing magnetic resonance tomography with diffusion-weighted imaging (DWI), stroke volumes of greater than 145 ml within 14 h of symptom onset [19] and of greater than 82 ml within 6 h [27] were found to be reliable predictors of a malignant course. More recently, multimodality monitoring including brain tissue oxygenation, cerebral metabolites by microdialysis, continuous and intracortical electroencephalography (EEG) revealed new insights into the development of malignant brain edema [38] [39] [40] 42, 43] . An increase in periinfarct extracellular glutamate, glycerin, and lactate concentration, and an augmentation of the lactate/ pyruvate ratio was thought to reflect developing brain edema with subsequent secondary neuronal ischemia, as those changes of neurochemicals preceded an increase in ICP [39, 43] . Impaired autoregulation, decreased brain tissue oxygenation, and low cerebral perfusion pressure (CPP) were shown surrounding the infarct [38, 40] . Bosche et al. [42] found significantly lower nontransmitter amino acid concentrations in the areas adjacent to the infarct in patients who developed malignant brain edema. The presence of a peak of faster EEG activity (5-7 Hz) in EEG power spectra obtained from continuous EEG monitoring after hemicraniectomy was correlated with an improved level of consciousness and functional outcome at discharge [44 & ]. Cortical spreading depression and peri-infarct depolarizations were seen on cortical EEG strips inserted during hemicraniectomy procedures in all patients with electrodes placed correctly in areas adjacent to infarcted tissue. The time for the EEG to recover was longer after clusters of cortical-spreading depressions indicating progressive deterioration of the metabolic or hemodynamic status in peri-infarct tissue [45] .
MANAGEMENT OF ACUTE ISCHEMIC INFARCTION
Successful recanalization of the hypoperfused or occluded MCA or ICA within a narrow time window of 3-4.5 h can be lifesaving and decrease the size of infarction, thereby preventing the development of malignant brain edema [46] [47] [48] [49] . Intravenous recombinant tissue plasminogen activator (rtPA) administered within 3 h of onset of the first stroke symptom is the only approved acute stroke treatment [46, 49, 50] . Extension of the time window up to 4.5 h has been demonstrated to be safe and efficacious [48] . However, intravenous thrombolysis is less likely to reperfuse large cerebral artery occlusions such as in 'malignant' MCA infarctions [51 & ]. The PROACT trials investigated safety and feasibility of intra-arterially administered recombinant prourokinase within 6 h of stroke onset. The recanalization rate was 66% with a 10% risk of intracerebral hemorrhage [52, 53] . A meta-analysis including 395 patients from five trials showed a rate of partial or complete vessel recanalization of 46.8% with intra-arterial fibrinolysis with 14.8% good and 13.0% excellent outcomes. The discrepancy between recanalization rates and outcomes may be explained by prolonged times from stroke onset to procedure [54] . In the meantime, several devices for mechanical recanalization have become available: the Mechanical Embolus Removal in Cerebral Ischemia (MERCI; Concentric Medical, Inc., Mountainview, California, USA, see Fig. 4 ), a corkscrewshaped device to pull the thrombus into an extracranial guide catheter under active suction; the Penumbra stroke system (Penumbra, Inc., Alameda, California, USA) for clot aspiration and extraction with catheter position proximal to the occlusion; Solitaire (Covidien/eV3, Maple Grove, Minnesota, USA), or Trevo (Concentric Medical, Inc., Mountainview, California, USA) which are combined removable stent and clot retriever devices [51 & ]. None of these devices have been evaluated in a randomized controlled trial regarding their effect on long-term outcome. Acute stenting and angioplasty of intracranial stenosis with the Wingspan stent system (Stryker/Target, Fremont, California, USA) increased the risk of recurrent stroke at 30 days [55] . Several other methods are currently under investigation, such as bridging of intravenous with intra-arterial rtPA and/or mechanical thrombus removal (Interventional Management of Stroke Trial 3, IMS3).
INTENSIVE CARE MANAGEMENT
Patients with 'malignant' MCA strokes are best managed in a neuroscience intensive care unit. Most patients require intubation, mechanical ventilation, and sedation for prophylaxis of aspiration or procedures if not for respiratory failure [56] .
Monitoring of ICP has not been proven to be more helpful than neurological examination and repeated CT scanning. Twelve of 19 patients with ICP monitors did not present with ICP rise by monitor, despite increases in midline shift at least !5 mm at the level of septum pellucidum, uncal herniation, cisternal effacement by CT, or anisocoria by clinical examination [15 & ]. Medical management of cerebral edema consists of head of bed elevation (308), osmotherapy with mannitol or hypertonic saline, sedation, and hypothermia. None of these treatments has been studied in a randomized controlled trial [57] . Bolus administration of 23.4% hypertonic saline led to rapid reversal of transtentorial herniation in 75% of 68 patients including eight patients with ischemic stroke [58] . Direct comparison of equiosmolar doses of 20% mannitol and 23.4% hypertonic saline in nine patients with 'malignant' MCA stroke with greater than 2 mm midline shift at the pineal gland or septum pellucidum level demonstrated comparable minimal effects on cerebral blood flow (CBF) utilizing positron emission tomography at normal blood pressures. When the blood pressure was elevated, the agents led to a rise in CBF in the 99mTc-DTPA SPECT, 99m technetium-diethylenetriaminepenta-acetic acid single-photon emission computed tomography; 99mTc-ECD SPECT, 99m technetium-ethylcysteinate-dimer single-photon emission CT; ACA, anterior cerebral artery; ADC, apparent diffusion coefficient; BP, blood pressure; CI, confidence interval; CPP, cerebral perfusion pressure; CT, computed tomography; DWI, diffusion-weighted imaging; MCA, middle cerebral artery; NIHSS, National Institute of Health Stroke Scale; pbtO 2 , partial brain tissue oxygen pressure; OR, odds ratio; PCA, posterior cerebral artery; PET, positron emission tomography; TTP, time to peak on magnetic resonance imaging perfusion maps.
hemisphere not affected. Cerebral blood volume remained unchanged after administration of both therapies [59] . In general, most neurointensivists favor the use of hypertonic saline (55% vs. mannitol 45%) for a reduced frequency of rebound edema, a longer duration of effect, desired volume expansion, and lack of systemic side-effects [62] .
Systemic hypothermia (target temperature 33-358C) for ICP control can be achieved with ice packs, intravenous cold saline solutions, cooling blankets, surface and intravascular cooling devices. There are a few safety trials, but no efficacy studies, despite reliable demonstrations of reduced infarct size with variable levels and duration of hypothermia after ischemic stroke in animal models [63] . In one safety trial, 25 patients with large MCA territory infarcts underwent moderate hypothermia (338C) after an interval of 14 AE 7 h after stroke onset. Hypothermia was maintained for 48-72 h. ICP was reduced, but the patients were subjected to passive rewarming (17-24 h) which resulted in a continuous rise of ICP with subsequent herniation and death in nine patients (44% mortality). Complications of hypothermia encompassed shivering, cardiac arrhythmias including prolongation of the PR and QT interval, ventricular ectopy and fibrillation, sepsis, pneumonia, thrombocytopenia, as well as augmentation of serum amylase and lipase with unknown clinical significance [64] . Controlled rewarming at 0.1-0.28C over 2-4 h correlated with a gradual increase of ICP, decrease of CPP, and improved cerebral cellular and metabolic compensation mechanisms [65] . In a large prospective trial of 50 patients treated with moderate hypothermia (32-338C) for 72 h after large hemispheric infarction, ICP was significantly reduced. Passive rewarming within 16 h was associated with a pronounced rise in ICP compared to controlled rewarming over a longer period of time (>16 h). The most common side-effects of hypothermia in this study were cardiac arrhythmias (sinus bradycardia, prolonged PR and QT intervals), arterial hypotension, pneumonia, decreased serum potassium, thrombocytopenia, and coagulopathy. Mortality was 38% overall. All patients received midazolam and propofol for sedation, morphine and fentanyl for analgesia, and neuromuscular blockade with vecuronium and atracurium during hypothermia and rewarming [66] . In another study, 36 patients with space-occupying MCA infarction were treated with moderate hypothermia (338C) if the dominant hemisphere was affected (19 patients) and compared to patients with nondominant hemispheric infarctions treated with hemicraniectomy (17 patients). Mortality was 47% in the hypothermia group (hemicraniectomy group 12%): one patient died of sepsis and three of rebound intracranial hypertension after rewarming. The application of hypothermia led to a prolonged application of higher doses of vasopressors to treat hypotension [67] . A case series reports 12 patients treated with moderate hypothermia (32-338C) 24 h after stroke onset until evidence of resolution of mass effect by CT, followed by slow rewarming over 2-5 days. Most common side-effects encompassed systemic hypotension, thrombocytopenia, and hyperfibrinogenemia. Five patients died of herniation before and after the rewarming phase [68] . Moderate hypothermia (358C) was introduced after hemicraniectomy in 12 of 25 patients for 48 h. There was no difference in mortality, but a trend to better functional outcome was done using National Institute of Health Stroke Scale (NIHSS) and Barthel Index at 6 months in the group treated with hemicraniectomy and hypothermia [69] . In summary, the use of hypothermia for control of cerebral edema in large hemispheric infarction is well tolerated and feasible, its efficacy needs to be evaluated in randomized clinical trials. The DEcompressive surgery Plus hypothermia in Space-Occupying Stroke (DEPTH-SOS) study, a randomized trial of moderate hypothermia after hemicraniectomy, is currently ongoing.
DECOMPRESSIVE SURGERY
Horizontal and vertical tissue shifts, ventricular and vascular compression by massive brain edema are relieved by removal of the bone flap over the frontal, temporal, and parietal lobe at the infarct site. This allows the edematous brain to expand extracranially, improves CPP and retrograde flow in the MCA, preserves CBF, and may prevent further ongoing ischemia. An adequate craniectomy needs to cover a large surface area, ideally beyond the margins of the infarction in all directions. Beginning with an appropriate scalp incision, the bone flap includes frontal, temporal, and parietal bone. The limiting factor is its anterior-posterior diameter, as the vertical diameter cannot exceed 9-10 cm from the floor of the middle fossa to the sagittal sinus. The target diameter should be 14 cm anterior-posterior, temporal bone needs to be removed down to the middle fossa. An increase in the anterior-posterior diameter from 12 to 14 cm results in an increase of potential volume by 76%. A small diameter hemicraniectomy leads to compression and kinking of bridging veins, or mushroom-like herniation of the brain with shearing distortion and additional ischemic lesions [70 & ] (Fig. 5) . A new method to maximally enlarge the surface covered by the craniectomy encompasses five keyholes: below the crossing of the superior temporal line with the frontozygomatic suture, 1 cm above the zygomatic root, 4 cm above the ipsilateral mid-pupil, 1.5 cm lateral to the midline, and 4 cm lateral and 6 cm above the inion [71] . After resection of the temporal bone to the skull base, the dura is opened, adjusted, and a biconvex dural patch is placed into the incision (duroplasty) to prevent leakage of cerebrospinal fluid. Resection of the infarction is not advisable as the margins between infarct and penumbra are poorly defined. The bone flap can be conserved in the abdominal subcutaneous tissue or in a cooled sterile isotonic solution. Reimplantation of the bone flap is possible 6-12 weeks up to 6 months after removal, once the swelling has resolved. Decompressive craniectomy was found to be well tolerated after intra-arterial thrombolysis [72] . Potential periprocedural complications include intracranial, wound and bone flap 6 ) presents with orthostatic headaches, focal signs, or seizures. The presumed cause is the pressure gradient between the atmosphere and the intracranial vault. Those patients tend to have a smaller surface of the craniectomy with larger lesion size which leads to increased areas of atrophy, a longer delay to reinsertion of the bone flap or cranioplasty, and a larger baseline stroke volume. They are generally older. Death may occur from 'paradoxical herniation'. Treatment includes placement in supine position, epidural blood patch, and cranioplasty as soon as possible [74,75 & ].
Multiple case series, clinical trials, and a metaanalysis suggest that timing of hemicraniectomy and age of the patients are crucial factors in determining outcome. Early surgery has a greater impact on reduction of mortality, and young patients (<50, 52, and 60 years) tend to have a better outcome [78] [79] [80] [81] [82] [83] . Although many clinicians are reluctant to offer hemicraniectomy to patients with dominant hemisphere infarcts, a meta-analysis found no difference in functional outcome comparing left vs. right-sided [79] . Five randomized controlled trials comparing decompressive hemicraniectomy have started in the past decade. The results of the four completed trials and a subsequent pooled analysis are listed below [6] [7] [8] [9] 84] . The Philippine HeMMI (Hemicraniectomy for Malignant Middle cerebral artery Infarcts) trial is still ongoing.
The North American Hemicraniectomy and Durotomy for Deterioration From Infarction Related Swelling Trial (HeaDDFIRST) enrolled 26 patients. Inclusion criteria were age 18-75 years and evidence of complete MCA/ICA infarction (>50% MCA territory, >90 ml volume by CT). The patients were first managed in the intensive care unit with defined protocols including glucose and fever control, did not receive prophylactic ICP treatment, and got a follow-up CT. Randomization to decompressive surgery within the next 4 h or to medical management was allowed if the CT scan revealed a septal shift greater than 7.5 mm and/or pineal shift greater than 4 mm. The results are shown in Table 2 . There was one crossover from the surgical to the medical arm. Short-term and long-term mortality as well as discharge status at 1 year did not differ between the groups. The trial has not been published [84] .
The German Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY) study included 32 patients, aged 18-60 years who presented with a NIHSS of 18 for nondominant and 20 for dominant hemisphere infarctions. Two-thirds of MCA territory and at least part of the basal ganglia had to be involved on CT. Randomization to surgical or medical management and treatment took place within 12-36 h. The study had a sequential design: a 40% difference of mortality was assumed between the groups and was therefore terminated when short term mortality reached a significant difference (P ¼ 0.019). However, functional outcome at 6 and 12 months was not statistically different (Table 3) . There were more dominant infarctions with higher NIHSS scores in the medical group, and 80% of the patients were enrolled at two centers only [7] . The French Decompressive Craniectomy in Malignant Middle Cerebral Artery Infarction (DECIMAL) trial was stopped after enrollment of 38 patients less than 55 years old with a NIHSS greater than 16 and altered level of consciousness because of the dramatic difference in mortality at 30 days (Table 4 ). The radiological inclusion criterion was stroke volume greater than 145 ml on DWI. The patients were randomized to decompressive surgery vs. best medical management within 30 h of infarction. The mean time to decompression was 20 h. Significantly more patients had better outcomes at 6 and 12 months. Younger age correlated with better outcome, and an infarct volume greater than 200 ml was the greatest predictor of mortality [9] .
The Dutch Hemicraniectomy After Middle cerebral artery infarction with Life-threatening Edema Trial (HAMLET) studied 64 patients with 18-60 years of age and a stroke covering more than two-thirds of the MCA territory and evidence of space-occupying edema on CT. The patients were randomized to decompression or medical therapy within 96 h of symptom onset. There were no differences in functional outcomes between the groups including Barthel index, depression scales, and quality of life (Table 5 ). For patients treated within 48 h, hemicraniectomy provided better outcomes. However, the study was terminated early because a difference in functional outcome seemed unlikely [6] .
The pooled analysis of the DESTINY, DECIMAL, and HAMLET trials initially included 93 patients, 18-60 years of age, with a NIHSS greater than 15 and MCA infarctions greater than two-thirds of the MCA territory on CT or a volume greater than 145 ml on DWI, who were randomized to decompressive surgery or medical management within 48 h of symptom onset. The results are shown in Table 6 . The number needed to treat (NNT) for survival with severe disability [inability to walk or to attend bodily needs, modified Rankin Scale (mRS) 4] at 1 year was 2. To achieve moderate disability with the ability to walk with assistance (mRS 3), the NNT was 4. There were no differences in chosen subgroups older than 50 years, patients with aphasia, or patients randomized and treated within 24 h [8] . This analysis was repeated after the completion of HAMLET with 109 patients. Decompressive surgery resulted in an absolute risk reduction of 50% for mortality, 42% for mRS 4, and 16% for mRS 3. For mortality and severe disability (mRS 4), the NNT remained 2, to achieve moderate disability (mRS 3) it increased to 6 [73] . On the basis of these trials and analysis, treatment of spaceoccupying infarction with hemicraniectomy within 48 h of MCA or ICA stroke in patients younger than 60 years received a level I recommendation in the guidelines [47] .
However, according to the criteria of the clinical trials, only 0.3% of a cohort of 2227 patients with ischemic stroke were eligible for hemicraniectomy within the defined time window [5] .
More questions remained: (1) The earlier the better? (2) Up to what age? and (3) What about the quality of life after hemicraniectomy?
(1) The mortality benefit was greater if surgery was performed within 24 h compared to more than 24 h (16 vs. 34%; 37 vs. 80%) in two series [78, 81] . Within 6 h of stroke onset, mortality was reduced to 9% [78] . There was no benefit for mortality and severe disability if hemicraniectomy was undertaken beyond 48 h in HAMLET [6] . The pooled analysis did not demonstrate any difference in outcome if surgery was done less or greater than 24 h after symptom onset [8] .
Selection of patients for hemicraniectomy too early after symptom onset may lead to unnecessary surgical procedures, whereas if hemicraniectomy is carried out after the point of herniation it was certainly too late. (2) About 40% of patients with 'malignant' MCA infarction are older than 60 years [1, 83] . The HAMLET study suggested that patients aged 51-60 years may benefit more from surgical decompression than patients 50 years old and younger [6] . The ongoing DESTINY II study includes patients older than 60 years who are randomized to hemicraniectomy or medical management within 48 h of symptom onset [85] . (3) An important question not addressed by the larger randomized trials is: What level of functional outcome is acceptable to individual patients? What is their perceived quality of life? The mRS mainly addresses motor skills. Depression, neuropsychological and cognitive deficits, as well as aphasia may impact the patient's life more than the inability to walk. In recent follow-up studies and decision analysis, patients tended to report satisfactory quality of life with moderate disability and with dominant hemispheric strokes after hemicraniectomy [86, 87] . Retrospective consent to hemicraniectomy depended on functional outcome at 1 year, patients with severe disability (mRS of 5) would not consent to surgery and reported a low quality of life [88] . In a study of neuropsychological outcome of 20 survivors after hemicraniectomy, more than two-thirds had developed dementia with abnormalities in every cognitive domain tested [89 & ]. The registry of 'malignant'
MCA infarctions, DESTINY-R, and a questionnaire to patients, families, and physicians about their expectations from a treatment with hemicraniectomy after space-occupying infarction and acceptable outcomes, DESTINY-S will continue to illuminate this issue.
CONCLUSION
Space-occupying edema after large hemispheric infarctions is difficult to control with conservative intensive medical management. Decompressive hemicraniectomy can save lives after large hemispheric infarction; most patients live with moderate-to-severe disability. The perceived quality of life and neuropsychological deficits after hemicraniectomy need further investigation, so does the timing for surgery and appropriate age limits. The correct patient selection for hemicraniectomy is of utmost importance to limit risks and provide maximum benefit. The only valid predictor of a malignant course seems to be the size of infarction, greater than 50% of MCA territory on CT and greater than 145 ml volume on DWI within 14 h of stroke onset (>82 ml on ADC or DWI within 6 h). Further investigation of multimodality monitoring with probes inserted adjacent to the infarct may refine the selection of patients who develop cerebral edema. Hypothermia is a promising additional tool for control of cerebral edema with a beneficial neuroprotective effect that requires further investigation.
